Trial Profile
Phase III trial of MelCancerVac for treatment of colorectal cancer
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 23 Oct 2023
Price :
$35
*
At a glance
- Drugs Dendritic-cell-vaccine-Enochian-Biosciences (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms VIVA
- 29 Apr 2015 According to DanDrit media release, it has signed a final collaboration agreement with GISCAD Foundation, a highly recognized Italian group with a focus on digestive tract cancer studies and that GISCAD has agreed to direct this important clinical trial.
- 26 Feb 2015 New trial record